Finasteride vs. Dutasteride for Men's Hair Loss: What's the Difference?
Both medications can help slow male-pattern hair loss. But they aren't identical—and understanding the differences can help you and your physician decide which treatment makes sense for you.
If you've researched medications for male-pattern hair loss, you've probably encountered finasteride. It's been prescribed for decades and remains one of the most established treatments for androgenetic alopecia.
But there's another medication you may have heard about: dutasteride.
Dutasteride works similarly to finasteride, but it suppresses the hormone associated with male-pattern hair loss more strongly. Research suggests it may produce greater hair growth in some men.
So why isn't everyone taking dutasteride instead?
The answer involves effectiveness, side effects, FDA approval, and individual treatment goals.
How do finasteride and dutasteride work for hair loss?
Male-pattern hair loss, also called androgenetic alopecia, is influenced by genetics and a hormone called dihydrotestosterone (DHT).
In genetically susceptible people, DHT contributes to the gradual shrinking of hair follicles. Over time, affected follicles produce thinner, shorter hairs, eventually leading to visible thinning or baldness.
Finasteride and dutasteride belong to a class of medications called 5-alpha-reductase inhibitors. They reduce the conversion of testosterone into DHT.
The difference is how they do it.
Finasteride primarily inhibits type II 5-alpha-reductase, an enzyme involved in DHT production.
Dutasteride inhibits both type I and type II 5-alpha-reductase, resulting in more extensive DHT suppression.
At commonly studied doses, finasteride 1 mg reduces circulating DHT by approximately 70%, while dutasteride 0.5 mg reduces it by more than 90%.
But greater DHT suppression doesn't automatically mean better results for every patient.
Is dutasteride more effective than finasteride?
Research suggests that dutasteride may produce greater improvements in hair growth for some men.
Clinical trials comparing dutasteride 0.5 mg daily with finasteride 1 mg daily have generally found greater improvements in hair counts and photographic assessments with dutasteride.
A large randomized trial involving 917 men found that dutasteride 0.5 mg produced significantly greater improvements in hair count and hair width than finasteride 1 mg after 24 weeks.
Subsequent systematic reviews and meta-analyses have generally supported those findings.
However, the certainty of some comparative evidence is limited, particularly regarding longer-term outcomes. Individual responses also vary.
Some men achieve excellent results with finasteride and have no reason to change treatment. Others continue to experience progressive thinning despite consistent use.
The most effective medication isn't necessarily the one that produces the greatest average improvement in a clinical trial. It's the one that offers the best balance of benefit and risk for you.
Why is finasteride FDA-approved for hair loss but dutasteride isn't?
Finasteride 1 mg is FDA-approved for treating male-pattern hair loss.
Dutasteride is FDA-approved in the United States for benign prostatic hyperplasia (BPH), a condition involving enlargement of the prostate.
Although dutasteride has been studied for male-pattern hair loss and is approved for that indication in some other countries, including Japan and South Korea, it does not have FDA approval for hair loss in the United States.
When a physician prescribes dutasteride for hair loss, it's considered off-label prescribing.
Off-label prescribing means using an FDA-approved medication for a condition, dose, or patient population outside its approved labeling.
It doesn't automatically mean the treatment is experimental or inappropriate. But it does mean the FDA hasn't approved that particular use, and the available evidence and potential risks need to be considered carefully.
Finasteride vs. dutasteride: What are the side effects?
Because finasteride and dutasteride work through similar mechanisms, they share many potential side effects.
These can include:
- Decreased sexual desire
- Erectile or ejaculatory difficulties
- Breast tenderness or enlargement
- Mood changes, including depression
- Changes in semen parameters that may affect fertility
These effects don't occur in everyone, and many patients tolerate treatment well.
Depression and suicidal ideation have been reported in patients taking finasteride. Patients should be aware of potential mood changes and seek prompt medical attention if they experience depression or thoughts of self-harm. Evidence concerning these risks with dutasteride is less established.
Some sexual side effects have been reported to persist after discontinuation of finasteride. Persistent symptoms have also been reported with dutasteride, although the frequency and relationship to treatment remain uncertain.
Both medications can lower prostate-specific antigen (PSA) levels, which can affect the interpretation of prostate cancer screening tests. Anyone taking finasteride or dutasteride should inform the clinician interpreting their PSA results.
The available comparative studies haven't consistently demonstrated a major difference in short-term sexual side effect rates between the two medications. However, long-term comparative safety data for hair-loss treatment are more limited.
How long does dutasteride stay in your system compared with finasteride?
One of the most important differences between these medications is how long they remain in the body.
Finasteride has a relatively short elimination half-life of approximately 5–6 hours in younger adult men.
Dutasteride has a much longer terminal half-life of approximately five weeks at therapeutic concentrations.
That means dutasteride can remain detectable for several months after treatment is stopped.
This doesn't mean its clinical effects disappear immediately when finasteride is discontinued, either. Hair follicles respond slowly to hormonal changes, and hair-loss treatment benefits can take months to change.
But dutasteride's prolonged persistence is an important consideration when discussing side effects, medication changes, fertility planning, and reproductive safety.
How long does finasteride take to work?
Hair growth changes slowly, and both medications require patience.
With finasteride, some improvement or stabilization may become noticeable within several months, but a fuller assessment of treatment response often takes approximately 12 months.
Dutasteride has demonstrated improvements in clinical trials by 24 weeks, although longer-term head-to-head comparisons remain limited.
Treatment success doesn't always mean visible regrowth. Slowing or preventing further hair loss can also be a meaningful benefit.
Photographs taken several months apart, using similar lighting and angles, can help evaluate changes more objectively.
If you've been taking finasteride for only a few months, switching medications may be premature.
What if finasteride isn't working for hair loss?
If you've been taking finasteride consistently but continue to notice thinning, the next step isn't necessarily switching medications.
Your physician may first consider:
- Treatment duration: Have you taken finasteride long enough to evaluate its effect?
- Treatment response: Has your hair loss continued to progress, or has it stabilized without noticeable regrowth?
- Diagnosis: Is male-pattern hair loss the only cause of your thinning?
- Other treatments: Would adding or adjusting minoxidil be reasonable?
- Side effects and medical history: Would a different treatment offer an acceptable balance of benefits and risks?
For some men, dutasteride may be worth considering after an inadequate response to finasteride.
For others, continuing finasteride or adjusting another part of the treatment plan may be preferable.
Can you switch from finasteride to dutasteride?
Yes. A physician may recommend switching from finasteride to dutasteride when clinically appropriate.
However, there isn't one universally established switching protocol for hair-loss treatment.
Because dutasteride remains in the body for a long time, medication changes should be planned with an understanding of its prolonged effects.
Taking both medications together isn't routinely necessary, and combining them should not be assumed to produce better results.
Never increase your dose, combine medications, or switch treatments without discussing the change with your prescribing clinician.
Does finasteride or dutasteride affect male fertility?
Both medications can affect semen parameters in some men, including sperm count, semen volume, or motility.
These changes are often reversible after discontinuation, although recovery can vary. Some studies and case reports have described prolonged abnormalities in semen parameters, but the frequency, duration, and clinical significance of these findings remain uncertain.
If you're experiencing fertility difficulties, have known abnormalities in semen parameters, or are actively planning to conceive, discuss these considerations with your physician before starting or changing treatment.
Finasteride and dutasteride can interfere with male fetal development if a pregnant person is exposed to sufficient amounts of the medication. Pregnant individuals should avoid handling crushed or broken finasteride tablets or leaking dutasteride capsules. The risk associated with exposure through a male partner's semen is considered very low.
Dutasteride also has specific blood donation restrictions because it remains in the body for an extended period.
Your physician or pharmacist can explain the precautions relevant to your medication.
What about topical finasteride?
Topical finasteride is another treatment option being studied for male-pattern hair loss.
It is applied directly to the scalp, with the goal of reducing systemic exposure compared with oral finasteride.
Some clinical studies suggest that topical finasteride can improve hair growth while producing lower blood concentrations than oral treatment.
However, systemic absorption still occurs, and lower exposure doesn't eliminate the possibility of adverse effects.
Topical finasteride is not FDA-approved for hair loss in the United States. Available compounded preparations may also differ in formulation and concentration.
For patients concerned about systemic side effects, it may be worth discussing topical treatment options with a dermatologist.
Which is better for hair loss: finasteride or dutasteride?
Both medications are reasonable treatments to consider for male-pattern hair loss, but they aren't interchangeable in every situation.
Finasteride has a long history of use, FDA approval for male-pattern hair loss, and substantial evidence supporting its effectiveness.
Dutasteride produces stronger DHT suppression and may offer greater hair-growth benefits for some men, but its use for hair loss in the United States is off-label, and it remains in the body much longer.
The right choice depends on your treatment history, response, medical circumstances, and preferences.
For women considering these medications, the evidence and prescribing considerations are different, particularly around reproductive safety and menopause.
More treatment options. Individualized care.
Many online hair-loss services offer finasteride as a standard treatment but don't include dutasteride in their prescribing options.
At Verilane Hair, our physicians can consider both medications, along with oral minoxidil and other appropriate treatments.
We review your hair-loss history, previous medications, treatment response, and relevant medical information before recommending a plan.
That might mean continuing finasteride, considering dutasteride, adding another treatment, or recommending further evaluation.
Your prescription is sent to the pharmacy you choose, without a required subscription pharmacy or proprietary compounded formula.
Considering a change in hair-loss treatment?
Whether you're starting treatment or wondering if finasteride is still the right choice, Verilane Hair offers individualized physician evaluation and treatment options beyond a standard prescribing menu.
Start a Hair Visit — $44All treatment decisions are based on physician review and clinical appropriateness. Dutasteride is not FDA-approved for hair loss in the United States. A particular medication or prescription is not guaranteed. Some patients may require laboratory testing, an in-person examination, or specialty care.
Medical review: Lindsey McIlvena, MD, MPH
Last reviewed: October 2026
References
- Wang Z, Gu B, Sharkey C, Ge R, Olumi AF. SRD5A2 and Emerging Therapies in Androgen-Driven Disorders. Nature Reviews Urology. 2026.
- Kelly Y, Blanco A, Tosti A. Androgenetic Alopecia: An Update of Treatment Options. Drugs. 2016.
- Saceda-Corralo D, Domínguez-Santas M, Vañó-Galván S, Grimalt R. What's New in Therapy for Male Androgenetic Alopecia? American Journal of Clinical Dermatology. 2023.
- Gupta AK, Venkataraman M, Talukder M, Bamimore MA. Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatology. 2022.
- Zhou Z, Song S, Gao Z, et al. The Efficacy and Safety of Dutasteride Compared With Finasteride in Treating Men With Androgenetic Alopecia: A Systematic Review and Meta-Analysis. Clinical Interventions in Aging. 2019.
- Quintero T, Gratz B, Pepperney L, Rosenstadt J, Gallicano GI. Impact of 5-Alpha Reductase Inhibitors on Male Reproductive Health: A Review of Finasteride and Dutasteride. Reproductive Toxicology. 2026.
- Huang KP, Senna MM. Hair Are the Rankings—5-α Reductase Inhibitors and Minoxidil in Male Androgenetic Alopecia. JAMA Dermatology. 2022.
- Devjani S, Ezemma O, Kelley KJ, Stratton E, Senna M. Androgenetic Alopecia: Therapy Update. Drugs. 2023.
- Gupta AK, Talukder M. Efficacy and Safety of Dutasteride in the Treatment of Alopecia: A Comprehensive Review. Expert Opinion on Pharmacotherapy. 2025.
- Liu Y, Tosti A, Wang ECE, et al. Androgenetic Alopecia. Nature Reviews Disease Primers. 2025.
- Laanani M, Weill A, Jollant F, Zureik M, Dray-Spira R. Suicidal Risk Associated With Finasteride Versus Dutasteride Among Men Treated for Benign Prostatic Hyperplasia: Nationwide Cohort Study. Scientific Reports. 2023.
- Gong Z, He J, Feng Q, et al. Androgenetic Alopecia Drugs and Male Infertility: Evidence From Pharmacovigilance and Testicular Transcriptomics. PLOS ONE. 2026.